MedWatch

GN Hearing disappoints despite high Q2 growth – maintains annual guidance

The hearing aid supplier notes a high level of growth in the second quarter of the year following last year's headwinds during the same period. However, despite revenue surging ahead, the operating margin underperforms, contrary to analyst estimates. GN Hearing maintains its financial outlook for the year.

GN Hearing presents it Q2'21 report Thursday morning. | Photo: GN Store Nord / PR

After a catastrophic second quarter last year resulting from the coronavirus pandemic, GN Hearing closes Q2 of 2021 in far better shape, shows the company's interim financial statement published Thursday morning.

Among other things, the report books quarterly revenue of DKK 1.332bn, a substantial increase from last year's 55 percent slump to a Q2 top line of DKK 715m.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Lundbeck chairman demands change: "We can't live with this"

Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.

Further reading

Related articles

Trial banner

Latest news

See all jobs